Chapter 2608 [2608] Such a big guy


    While eating, I chatted with Mr. Tan about scientific research.


    Tan is an expert inparoscopy, general surgery, and oncology in digestive tract and gastrointestinal surgery. Mr. Tan''s traditional surgery is as first-ss asparoscopic surgery, and his extra-operative treatment n for tumor patients is also first-ss.


    It would be ridiculous to imagine that the scope of academic research that Mr. Tan can do is limited toparoscopy. For example, the immortal brother rarely does heart transnts, but he will study assistive devices for end-stage heart treatment.


    For surgeons, doing scientific research and surgery is an advantage, which is reflected in the ability to conduct research on various operations. On the other hand, in the field of basic subjects, surgeons have the advantage of taking advantage of the pathological specimens obtained by surgeons.


    It is all too easy for surgeons to capture surgical pathology specimens of various patient tumors during surgery. Unlike other departments, it is difficult to get a pathological specimen that you want. Specimens obtained by medical endoscopy are limited in scope, far inferior to surgery. In this way, you will find that surgeons who do basic research can actually be better than shoulder physicians and pathologists.


    Mr. Tan happens to be such a big guy.


    Specifically speaking about the topic of Mr. Tan''s research, it can be said that after entering the 21st century, there is arge ss of star anti-tumor drugs: targeted drugs.


    Targeted drugs are like arrows aimed at the tumor "chutu". Compared with chemotherapeutic drugs, they are like spraying pesticides when they attack the tumor. They have high precision and avoid damage to human healthy tissues. They are warmly weed by doctors and patients. The advantage of targeted drugs lies in uracy, and the uracy of targeted drugs is based on the target. Identifying the target of targeted drugs naturally bes the top priority of researchers.


    The study of targets is essentially inseparable from the study of tumor pathogenesis.


    The pathogenesis of tumors is intricate andplex, and there are many links and substances involved in the pathogenesis of tumors. In theory, everything can be a target. For example, the mostmon substance receptors, transporters, enzymes, ion channels, genes, etc., many of which are basic topics that have been studied. There is a rtively new research topic that was discovered and proposed in recent years, called microRNA.


    Micro RAN, a simple understanding, can be said to be a substance like the intestinal flora. Good microRNAs can inhibit tumor tissue after human absorption. Bad microRNAs promote the growth of tumor tissue. ording to this principle, if medical oncology studies the former, it can be made into a tumor suppressor. If you want to deal with the bad things in the back, it is most suitable to make a targeted drug with a "sudden" blow.


    Medicine found that it is better to kill the tumor than to suppress it. ording to the information known by Xie Wanying who came back from the future, it is a new trend of future targeted drugs.


    In any case, as mentioned earlier, to make targeted drugs, you must first identify the target, and to make RNA-targeted drugs, you need to find out the microRNA. The key topic of Mr. Tan is to study colon cancer microRNA, and a brand-new microRNA has been found in a wide range of colon cancer specimens. In theory, it can be the target of new targeted drugs for colon cancer. The key areas of scientific research are at the forefront.


    Tan''s research project is so cutting-edge, Xie Wanying must say that she can''t tell her teacher''s research.